Theracryf Plc
TCF.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | £1 | £2 | £10 | £10 |
| - Cash | £2 | £2 | £5 | £5 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | -£1 | £0 | £5 | £5 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -100% | -10.4% | – | – |
| Gross Profit | -£2 | £0 | £0 | -£0 |
| % Margin | – | 97.2% | 97.1% | – |
| EBITDA | -£2 | -£4 | -£5 | -£3 |
| % Margin | – | -896.2% | -1,129.6% | – |
| Net Income | -£2 | -£3 | -£4 | -£3 |
| % Margin | – | -792.2% | -914.7% | – |
| EPS Diluted | -0.004 | -0.011 | -0.015 | -0.01 |
| % Growth | 68.4% | 22.4% | -48.5% | – |
| Operating Cash Flow | -£2 | -£3 | -£4 | -£3 |
| Capital Expenditures | £0 | £0 | -£0 | -£0 |
| Free Cash Flow | -£2 | -£3 | -£4 | -£3 |